Medacta Group SA (SW:MOVE) — Market Cap & Net Worth
Market Cap & Net Worth: Medacta Group SA (MOVE)
Medacta Group SA (SW:MOVE) has a market capitalization of $2.91 Billion (CHF2.30 Billion) as of September 16, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #5034 globally and #76 in its home market, demonstrating a -8.41% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Medacta Group SA's stock price CHF115.40 by its total outstanding shares 19944514 (19.94 Million). Also see balance sheet size of Medacta Group SA for a full breakdown of the balance sheet.
Medacta Group SA Market Cap History: 2019 to 2026
Medacta Group SA's market capitalization history from 2019 to 2026. Data shows growth from $1.80 Billion to $2.91 Billion (2.65% CAGR). Also see MOVE cash flow metrics for how efficiently the company converts equity into cash flow.
Medacta Group SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Medacta Group SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check MOVE stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
4.55x
Medacta Group SA's market cap is 4.55 times its annual revenue
Latest Price to Earnings (P/E) Ratio
36.88x
Medacta Group SA's market cap is 36.88 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $1.80 Billion | $310.62 Million | $11.86 Million | 5.81x | 152.10x |
| 2020 | $2.18 Billion | $302.49 Million | $37.09 Million | 7.21x | 58.84x |
| 2021 | $3.54 Billion | $363.13 Million | $51.52 Million | 9.74x | 68.66x |
| 2022 | $2.58 Billion | $437.12 Million | $46.25 Million | 5.90x | 55.77x |
| 2023 | $3.15 Billion | $510.78 Million | $47.36 Million | 6.17x | 66.55x |
| 2024 | $2.69 Billion | $590.58 Million | $72.89 Million | 4.55x | 36.88x |
Competitor Companies of MOVE by Market Capitalization
Companies near Medacta Group SA in the global market cap rankings as of September 16, 2026. Review Medacta Group SA tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Medacta Group SA by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #126 globally with a market cap of $179.26 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #230 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #231 globally with a market cap of $108.12 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #242 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #126 | Abbott Laboratories | NYSE:ABT | $179.26 Billion | $103.09 |
| #230 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $93.80 |
| #231 | Stryker Corporation | NYSE:SYK | $108.12 Billion | $281.87 |
| #242 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Medacta Group SA Historical Marketcap From 2019 to 2026
Between 2019 and today, Medacta Group SA's market cap moved from $1.80 Billion to $ 2.91 Billion, with a yearly change of 2.65%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CHF2.91 Billion | -26.21% |
| 2025 | CHF3.94 Billion | +46.72% |
| 2024 | CHF2.69 Billion | -14.72% |
| 2023 | CHF3.15 Billion | +22.21% |
| 2022 | CHF2.58 Billion | -27.09% |
| 2021 | CHF3.54 Billion | +62.10% |
| 2020 | CHF2.18 Billion | +20.99% |
| 2019 | CHF1.80 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 15th, 2026 the market cap of Medacta Group SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.91 Billion USD |
| MoneyControl | $2.91 Billion USD |
| MarketWatch | $2.91 Billion USD |
| marketcap.company | $2.91 Billion USD |
| Reuters | $2.91 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Medacta Group SA
Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Latin America, North America, the Asia-Pacific, and Middle East and Africa. It offers personalized 3D planning tools for use in hip, knee, shoulder, joint replacement, sports medicine, and spine surgery. Medacta Group SA was founded in 1958 and is headquartered in Castel San Pietro, Switzerland.